{"id":"ivermectin-tablets","_chembl":{"chemblId":"CHEMBL6067487","moleculeType":"Unknown"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ivermectin Tablets","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:06:59.386404+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:07:06.438949+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ivermectin Tablets","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:07:07.247903+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glutamate-gated chloride channel modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:07:07.831310+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067487/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:07:07.725603+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:50:34.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:07:09.737201+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05500326","phase":"PHASE2","title":"Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2025-06-24","conditions":"Scabies; Itch, Scabies","enrollment":120},{"nctId":"NCT06918665","phase":"PHASE1","title":"HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation","status":"SUSPENDED","sponsor":"Murdoch Childrens Research Institute","startDate":"2026-07","conditions":"Scabies","enrollment":52},{"nctId":"NCT04311671","phase":"PHASE3","title":"Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2021-05-03","conditions":"Onchocerciasis","enrollment":12979},{"nctId":"NCT07286604","phase":"EARLY_PHASE1","title":"Ivermectin Repurposed for the Treatment of PKDL","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-03-02","conditions":"Post Kala Azar Dermal Leishmaniasis","enrollment":10},{"nctId":"NCT03876262","phase":"PHASE3","title":"Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medicines Development for Global Health","startDate":"2021-05-03","conditions":"Onchocerciasis","enrollment":323},{"nctId":"NCT04332068","phase":"PHASE2","title":"Ivermectin Safety in Small Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-11-18","conditions":"Scabies","enrollment":240},{"nctId":"NCT07145736","phase":"PHASE4","title":"Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2025-08-04","conditions":"Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection","enrollment":52000},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT05124691","phase":"PHASE2, PHASE3","title":"Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms","status":"TERMINATED","sponsor":"Barcelona Institute for Global Health","startDate":"2022-01-20","conditions":"Helminthes; Infestation, Intestinal","enrollment":1001},{"nctId":"NCT06184399","phase":"PHASE2","title":"Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2024-06-05","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":260},{"nctId":"NCT06282315","phase":"PHASE3","title":"Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness","status":"RECRUITING","sponsor":"Insud Pharma","startDate":"2025-09-01","conditions":"Soil-Transmitted Helminths","enrollment":20000},{"nctId":"NCT06251739","phase":"EARLY_PHASE1","title":"Repurposing Ivermectin for PKDL Treatment","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-30","conditions":"Post-kala-azar Dermal Leishmaniasis","enrollment":30},{"nctId":"NCT07045493","phase":"PHASE2","title":"Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh","status":"ENROLLING_BY_INVITATION","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-07-10","conditions":"Soil Transmitted Helminth (STH) Infections","enrollment":110},{"nctId":"NCT03967054","phase":"PHASE3","title":"Repeat Ivermectin Mass Drug Administrations for MALaria Control II","status":"COMPLETED","sponsor":"Brian Foy","startDate":"2019-07-13","conditions":"Malaria","enrollment":4124},{"nctId":"NCT04049851","phase":"PHASE2","title":"Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients","status":"COMPLETED","sponsor":"Center for Research on Filariasis and Other Tropical Diseases, Cameroon","startDate":"2022-04-07","conditions":"Onchocerciasis, Ocular, Loiasis","enrollment":72},{"nctId":"NCT05305560","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention","status":"COMPLETED","sponsor":"MedinCell S.A","startDate":"2022-03-25","conditions":"COVID-19","enrollment":400},{"nctId":"NCT06497075","phase":"","title":"Co-administration of IVM and ALB in School-based Deworming in Uganda","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2024-07-01","conditions":"Helminthiasis, Intestinal Worms","enrollment":8767},{"nctId":"NCT04056325","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2019-11-27","conditions":"Strongyloides Stercoralis Infection","enrollment":617},{"nctId":"NCT04700423","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2021-03-01","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":536},{"nctId":"NCT06373835","phase":"PHASE2","title":"Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2024-05-20","conditions":"Strongyloides Stercoralis Infection, Strongyloidiasis","enrollment":202},{"nctId":"NCT05056883","phase":"PHASE3","title":"A Phase III Confirmatory Study of K-237","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2021-10-22","conditions":"Covid19","enrollment":1030},{"nctId":"NCT06037876","phase":"PHASE3","title":"Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2023-10-09","conditions":"Trichuriasis","enrollment":161},{"nctId":"NCT06332872","phase":"PHASE4","title":"Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand","status":"ACTIVE_NOT_RECRUITING","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-12-15","conditions":"Pediculus Capitis Infestation, Permethrin Adverse Reaction, Dimethicone Adverse Reaction","enrollment":117},{"nctId":"NCT03527732","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of IVM/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2018-09-09","conditions":"Trichuriasis","enrollment":1673},{"nctId":"NCT05180461","phase":"PHASE2","title":"Emodepside Phase II Trial for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Drugs for Neglected Diseases","startDate":"2021-08-30","conditions":"Onchocerciasis","enrollment":578},{"nctId":"NCT04848688","phase":"PHASE3","title":"Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2022-02-05","conditions":"Strongyloides Stercoralis Infection","enrollment":332},{"nctId":"NCT04726969","phase":"PHASE3","title":"Efficacy and Safety of MOX/ALB Co-administration","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2021-06-15","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":255},{"nctId":"NCT05082753","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2020-11-19","conditions":"Anthelmintic Agent","enrollment":50},{"nctId":"NCT05946642","phase":"PHASE3","title":"Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2023-07-15","conditions":"Malaria","enrollment":13000},{"nctId":"NCT05894538","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2022-02-16","conditions":"Covid19","enrollment":1459},{"nctId":"NCT05993143","phase":"PHASE3","title":"Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50","status":"TERMINATED","sponsor":"Insud Pharma","startDate":"2021-01-18","conditions":"COVID-19, SARS-CoV-2","enrollment":249},{"nctId":"NCT05930002","phase":"NA","title":"Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-07-21","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05736861","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":1800},{"nctId":"NCT05819983","phase":"PHASE4","title":"Ivermectin/ Permethrin for Scabies","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2023-01-25","conditions":"Scabies","enrollment":60},{"nctId":"NCT05283954","phase":"PHASE2, PHASE3","title":"Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea","status":"WITHDRAWN","sponsor":"Oriol Mitja","startDate":"2022-05-01","conditions":"SARS-CoV2 Infection, COVID-19","enrollment":""},{"nctId":"NCT05477810","phase":"EARLY_PHASE1","title":"Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2022-09-13","conditions":"Bioequivalence","enrollment":16},{"nctId":"NCT00300768","phase":"PHASE2","title":"Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2006-09-06","conditions":"Onchocerciasis","enrollment":172},{"nctId":"NCT05231603","phase":"PHASE3","title":"Ivermectin for Post Exposure Prophylaxis of Covid-19","status":"TERMINATED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2022-02-16","conditions":"COVID-19","enrollment":50},{"nctId":"NCT05155527","phase":"PHASE2","title":"Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-02-10","conditions":"COVID-19","enrollment":200},{"nctId":"NCT05362513","phase":"PHASE1","title":"Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2021-06-01","conditions":"Scabies","enrollment":100},{"nctId":"NCT03576313","phase":"PHASE3","title":"Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-11","conditions":"Malaria","enrollment":4939},{"nctId":"NCT04844905","phase":"PHASE3","title":"Adjunctive Ivermectin Mass Drug Administration for Malaria Control","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-05-03","conditions":"Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis","enrollment":24000},{"nctId":"NCT04703205","phase":"PHASE2","title":"Study in COvid-19 Patients With iveRmectin (CORVETTE-01)","status":"UNKNOWN","sponsor":"Kitasato University","startDate":"2020-09-16","conditions":"Covid19","enrollment":214},{"nctId":"NCT04632706","phase":"PHASE1","title":"Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19","status":"COMPLETED","sponsor":"MedinCell S.A","startDate":"2020-09-22","conditions":"Covid19","enrollment":24},{"nctId":"NCT05060666","phase":"PHASE3","title":"Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]","status":"UNKNOWN","sponsor":"Infectopharm Arzneimittel GmbH","startDate":"2021-11","conditions":"Covid19","enrollment":412},{"nctId":"NCT05040724","phase":"PHASE3","title":"Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19","status":"UNKNOWN","sponsor":"Raincy Montfermeil Hospital Group","startDate":"2021-05-28","conditions":"To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care","enrollment":200},{"nctId":"NCT04673214","phase":"PHASE3","title":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","status":"COMPLETED","sponsor":"Gilberto Cruz Arteaga","startDate":"2020-12-16","conditions":"Covid19","enrollment":114},{"nctId":"NCT04403555","phase":"PHASE2, PHASE3","title":"Ivermectin as a Novel Therapy in COVID-19 Treatment","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-06-01","conditions":"COVID","enrollment":164},{"nctId":"NCT04529525","phase":"PHASE2, PHASE3","title":"Ivermectin to Prevent Hospitalizations in COVID-19","status":"COMPLETED","sponsor":"Instituto de Cardiología de Corrientes","startDate":"2020-08-19","conditions":"Covid19","enrollment":501},{"nctId":"NCT04944082","phase":"PHASE4","title":"Remdesivir- Ivermectin Combination Therapy in Severe Covid-19","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-07-01","conditions":"Covid19","enrollment":60},{"nctId":"NCT04937569","phase":"PHASE3","title":"Ivermectin Versus Standard Treatment in Mild COVID-19","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-07-01","conditions":"Covid19","enrollment":1644},{"nctId":"NCT04438850","phase":"PHASE2","title":"COVidIVERmectin: Ivermectin for Treatment of Covid-19","status":"TERMINATED","sponsor":"IRCCS Sacro Cuore Don Calabria di Negrar","startDate":"2020-07-31","conditions":"Covid19","enrollment":93},{"nctId":"NCT04854460","phase":"PHASE1","title":"Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2021-01-28","conditions":"Healthy","enrollment":30},{"nctId":"NCT04784481","phase":"PHASE1, PHASE2","title":"Ivermectin Reproposing for Mild Stage COVID-19 Outpatients","status":"COMPLETED","sponsor":"Ministry of Public Health, Argentina","startDate":"2020-09-20","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome)","enrollment":254},{"nctId":"NCT04832945","phase":"","title":"SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study","status":"COMPLETED","sponsor":"Grupo Rescue S.A.S República Dominicana","startDate":"2020-06-29","conditions":"Covid19","enrollment":713},{"nctId":"NCT04834115","phase":"PHASE3","title":"Efficacy of Ivermectin in Outpatients With Non-severe COVID-19","status":"UNKNOWN","sponsor":"Universidad Nacional de Asunción","startDate":"2020-11-17","conditions":"Covid19, Coronavirus Infection","enrollment":400},{"nctId":"NCT04729140","phase":"PHASE4","title":"An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization","status":"UNKNOWN","sponsor":"Max Health, Subsero Health","startDate":"2020-12-28","conditions":"Covid19","enrollment":150},{"nctId":"NCT04746365","phase":"PHASE4","title":"Ivermectin Role in Covid-19 Clinical Trial","status":"COMPLETED","sponsor":"Elaraby Hospital","startDate":"2020-12-06","conditions":"Covid19","enrollment":300},{"nctId":"NCT04407130","phase":"PHASE2","title":"Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-06-16","conditions":"COVID-19 Patients","enrollment":72},{"nctId":"NCT03517462","phase":"NA","title":"Ocular Changes After Ivermectin - (DOLF IVM/Oncho)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-08-06","conditions":"Onchocerciasis","enrollment":231},{"nctId":"NCT04390022","phase":"PHASE2","title":"Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2020-07-31","conditions":"Covid-19, Coronavirus Infection, SARS-CoV-2 Infection","enrollment":24},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","startDate":"2020-06-08","conditions":"Covid19","enrollment":600},{"nctId":"NCT04391127","phase":"PHASE3","title":"Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection","status":"COMPLETED","sponsor":"Centenario Hospital Miguel Hidalgo","startDate":"2020-05-04","conditions":"COVID-19","enrollment":108},{"nctId":"NCT04343092","phase":"PHASE1","title":"Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management","status":"COMPLETED","sponsor":"University of Baghdad","startDate":"2020-04-18","conditions":"COVID 19","enrollment":16},{"nctId":"NCT04446104","phase":"PHASE3","title":"A Preventive Treatment for Migrant Workers at High-risk of COVID-19","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2020-05-13","conditions":"Covid-19","enrollment":4257},{"nctId":"NCT04425863","phase":"","title":"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19","status":"COMPLETED","sponsor":"Eurnekian Public Hospital","startDate":"2020-05-01","conditions":"Severe Acute Respiratory Syndrome, Ventilation Pneumonitis","enrollment":167},{"nctId":"NCT04384458","phase":"NA","title":"Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis","status":"UNKNOWN","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2020-07-20","conditions":"Coronavirus Infections","enrollment":400},{"nctId":"NCT04422561","phase":"PHASE2, PHASE3","title":"Prophylactic Ivermectin in COVID-19 Contacts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-05-31","conditions":"COVID","enrollment":340},{"nctId":"NCT04510233","phase":"PHASE2","title":"Ivermectin Nasal Spray for COVID19 Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-09","conditions":"Covid19","enrollment":60},{"nctId":"NCT04392713","phase":"NA","title":"Efficacy of Ivermectin in COVID-19","status":"UNKNOWN","sponsor":"Combined Military Hospital, Pakistan","startDate":"2020-04-15","conditions":"COVID","enrollment":100},{"nctId":"NCT03036059","phase":"PHASE4","title":"Twice Yearly Treatment for the Control of LF","status":"COMPLETED","sponsor":"Noguchi Memorial Institute for Medical Research","startDate":"2017-05-19","conditions":"Lymphatic Filariasis, Helminth Infection","enrollment":1462},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":"Trachoma, Yaws, Lymphatic Filariases","enrollment":20000},{"nctId":"NCT03717558","phase":"PHASE1","title":"Bioavailability Pilot Study of Versus W0035 Versus Stromectol","status":"WITHDRAWN","sponsor":"Pierre Fabre Dermatology","startDate":"2018-04-30","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT00790998","phase":"PHASE3","title":"Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2009-04","conditions":"Onchocerciasis","enrollment":1497},{"nctId":"NCT03173742","phase":"PHASE1","title":"Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2016-03","conditions":"Helminthiasis","enrollment":54},{"nctId":"NCT02963324","phase":"PHASE1","title":"Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-11","conditions":"Malaria","enrollment":12},{"nctId":"NCT00921219","phase":"PHASE1","title":"Ivermectin Solution Bioequivalence Study - With Food (Repeat)","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2005-09","conditions":"Healthy","enrollment":34},{"nctId":"NCT00921674","phase":"PHASE1","title":"Ivermectin Solution Bioequivalence Study - With Food","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2005-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT00921154","phase":"PHASE1","title":"Ivermectin Solution Bioequivalence Study - Fasted","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2005-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT00819520","phase":"PHASE3","title":"Ivermectin in the Treatment of Head Lice","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2004-02","conditions":"Lice Infestations","enrollment":812}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL6067487"},"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Iverzine"],"phase":"marketed","status":"active","brandName":"Ivermectin Tablets","genericName":"Ivermectin Tablets","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:07:09.737201+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}